These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 9061312)

  • 1. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
    Stenvinkel P; Berglund L; Ericsson S; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 1997 Feb; 27(2):169-77. PubMed ID: 9061312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis.
    de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ
    Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) levels in relation to albumin concentration in childhood nephrotic syndrome.
    Noto D; Barbagallo CM; Cascio AL; Cefalù AB; Cavera G; Caldarella R; Marino G; Travali S; Cutaia I; Maringhini S; Notarbartolo A; Averna M
    Kidney Int; 1999 Jun; 55(6):2433-9. PubMed ID: 10354292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria.
    Warwick GL; Packard CJ; Demant T; Bedford DK; Boulton-Jones JM; Shepherd J
    Kidney Int; 1991 Jul; 40(1):129-38. PubMed ID: 1921148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipopheresis in the nephrotic syndrome.
    Brunton C; Varghese Z; Moorhead JF
    Kidney Int Suppl; 1999 Jul; 71():S6-9. PubMed ID: 10412726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P; Lu L; Hu B; Du PF
    Scand J Clin Lab Invest; 2009; 69(6):680-6. PubMed ID: 19468931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein metabolism in nephrotic syndrome in childhood.
    Oetliker OH; Mordasini R; Lütschg J; Riesen W
    Pediatr Res; 1980 Jan; 14(1):64-6. PubMed ID: 7360522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
    Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion.
    Stenvinkel P; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 2000 Oct; 30(10):866-70. PubMed ID: 11029600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women.
    Matthan NR; Welty FK; Barrett PH; Harausz C; Dolnikowski GG; Parks JS; Eckel RH; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1092-7. PubMed ID: 15087307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
    J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
    Ma L; Waldmann E; Ooi EMM; Chan DC; Barrett HPR; Watts GF; Parhofer KG
    Eur J Clin Invest; 2019 Feb; 49(2):e13053. PubMed ID: 30447089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein metabolism in the nephrotic syndrome.
    Warwick GL; Caslake MJ; Boulton-Jones JM; Dagen M; Packard CJ; Shepherd J
    Metabolism; 1990 Feb; 39(2):187-92. PubMed ID: 2299990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
    Arad Y; Ramakrishnan R; Ginsberg HN
    J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.